Effects of B-cell depletion on peripheral B-cell populations and serum cryoglobulin. (A) Histogram representing the percentage of CD19⁺ cells following rituximab in patients with HCV-MC vasculitis. (B) Residual B-cell populations after rituximab-mediated depletion (*P < .05, **P < .01). (C) Serum cryoglobulin level (g/L) during rituximab therapy in patients with HCV-MC vasculitis (**P < .01).